Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: Multicenter study of the Korean Cancer Study Group (KCSG).

Hongjae Chon,Hyung-Soon Park,Beodeul Kang,Hyeon-Su Im,Choong-kun Lee,Il-Hwan Kim,Myoung-Joo Kang,Jun-Eul Hwang,Woo Kyun Bae,Jaekyung Cheon,Jung Yong Hong,Jung Hun Kang,Jung Hoon Kim,Sung Hee Lim,Jin Won Kim,Ji-Won Kim,Changhoon Yoo,Hye Jin Choi,Joon Oh Park

Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: Multicenter study of the Korean Cancer Study Group (KCSG).

2020

Hongjae Chon
Hyung-Soon Park
Beodeul Kang
Hyeon-Su Im
Choong-kun Lee
Il-Hwan Kim
Myoung-Joo Kang
Jun-Eul Hwang
Woo Kyun Bae
Jaekyung Cheon
Jung Yong Hong
Jung Hun Kang
Jung Hoon Kim
Sung Hee Lim
Jin Won Kim
Ji-Won Kim
Changhoon Yoo
Hye Jin Choi
Joon Oh Park

4624Background: There is no clear consensus on the second-line treatment for patients with metastatic pancreatic cancer (mPC). The aim of this study was to compare the efficacy and tolerability bet...

Keywords:

Fluorouracil
Metastatic pancreatic cancer
Oncology
Cancer
multicenter study
Liposomal Irinotecan
Internal medicine
FOLFIRINOX
Pathology
Medicine
second line chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations